PDLI Phase II Remitogen NHL data
Protein Design Labs (PDLI) reported preliminary data from a Phase II study of its Remitogen (SMART 1D10) humanized antibody showing 1 partial response in 25 evaluable patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma (NHL). The primary endpoint of the 60-patient trial is the percent of patients who achieve a complete or partial response.
The company also said that 14 patients have disease progression, with 12 of these patients progressing prior to day 120. PDLI said that because of this early progression, it will amend the trial protocol to include more doses of the antibody earlier in the treatment course, and an additional 20 patients will be enrolled. Data were presented at the American Society of Hematology meeting in Orlando. ...